What is claimed is:

1. Micronised particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form.

2. Colistin sulphomethate sodium for the use as claimed in Claim 1 wherein the micronised powder is mixed with a carrier.

3. Colistin sulphomethate sodium for the use as claimed in Claim 2 wherein the carrier is lactose.

4. A composition comprising micronised colistin sulphomethate sodium as defined in Claim 1 and a carrier, in the absence of free liquid.

5. A composition as claimed in Claim 4 wherein the carrier is lactose.

6. A composition as claimed in Claim 4 or Claim 5 wherein the ratio of colistin sulphomethate sodium to carrier is from 5:1 to 1:2 by weight.

7. A composition as claimed in Claim 4 or Claim 5 wherein the ratio of colistin sulphomethate sodium to carrier is from 4:1 to 1:1 by weight.

8. The composition as claimed in any one of Claims 4 to 7 wherein at least 50% by volume of the carrier particles have an effective particle size in the range of 30-150 micrometers.

9. A composition as claimed in any one of Claims 4 to 8 wherein at least 50% by volume of the micronised colistin sulphomethate sodium has a particle diameter of less than 8 micrometers.

10. A composition as claimed in any one of Claims 4 to 9 wherein at least 25% of the particles of micronised colistin sulphomethate sodium have a diameter of less than 6 micrometers.

11. A composition as claimed in any one of Claims 4 to 10 wherein the micronised colistin sulphomethate sodium is prepared in the desired particle size range using a fluid energy mill.

sub A6

12. A process for the preparation of a composition as claimed in any one of Claims 4 to 11 which comprises mixing micronised colistin sulphomethate sodium and a carrier.

13. A pharmaceutical dosage form suitable for use with a dry powder inhaler comprising micronised colistin sulphomethate sodium wherein at least 90% by volume of the particles have a diameter less than 10 micrometers or a composition according to any one of Claims 4 to 11 and a container, said dosage having a content of below 10 wt % water.

14. A pharmaceutical dosage form according to Claim 13 wherein the container is a hard gelatin capsule.

sub A7

15. A capsule containing micronised colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers.

16. A capsule as claimed in Claim 15 containing from 10 to 200 milligrams of micronised colistin sulphomethate sodium.

17. A capsule as claimed in Claim 15 containing from 30 to 150 milligrams of micronised colistin sulphomethate sodium.

18. A capsule as claimed in any one of Claims 15 to 17 further comprising a carrier.

19. A capsule as claimed in Claim 18 when the carrier is lactose.

20. A capsule according to any one of Claims 15 to 19 which is opaque.

21. A capsule according to any one of Claims 15 to 19 or a composition according to any one of Claims 4 to 11 packed in an opaque container.

22. A capsule containing micronised colistin sulphomethate sodium when the micronised particles have a diameter of less than 10 micrometers, in unit dosage form.

23. A capsule according to any one of Claims 15 to 22 which additionally comprises a micronised bronchodilatory drug.

24. A capsule according to Claim 23 wherein the bronchodilatory drug is salbutamol.

25. A capsule according to Claim 23 or Claim 24 which comprises from 50 to 150 milligrams of colistin sulphomethate sodium and from 1 to 250 micrograms of bronchodilatory drug

26. Micronised particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form.

27. Colistin sulphomethate sodium for the use as claimed in Claim 26 wherein the micronised powder is mixed with a carrier.

28. Colistin sulphomethate sodium for the use as claimed in Claim 27 wherein the carrier is lactose.

add A11